Can COGT Beat BPMC/SNY in Systemic Mastocytosis?

If you are looking for another interesting company to diligence, check out COGT. They are trying to develop a therapeutic that would compete with BPMC's lead drug AYVAKIT® (avapritinib) to treat Systemic Mastocytosis (SM). BPMC announced yesterday that it agreed to be acquired by SNY for ~$9B, whereas COGT has a current market cap around $650M and EV ~$500M. Thus, if COGT were successful to develop a therapeutic to displace AYVAKIT, investors would be handsomely rewarded.

COGT is down greater than 50% since last November. We have not followed COGT's results since last November closely to better understand whether the selloff is warranted. We likely will spend some time in the coming weeks doing that because COGT has some big readouts coming next month and by end of year in SM. Plus, they are in a number of our model portfolios, because COGT has been a hedge fund favorite. If we find some helpful info re: COGT's updated data/info since last November, we will report backvin the BPIQ Elite forum.

#COGT #BPMC #SNY

---

This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.

Article history:

First published 6/5/25 EJV & AV